DSB

Desktop Metal and DSB Technologies Driving Metal Binder Jetting into Production with X-Series Lineup

Retrieved on: 
Tuesday, September 12, 2023
Other Manufacturing, Technology, Steel, Engineering, Manufacturing, Software, Machinery, Machine Tools, Metalworking & Metallurgy, Electronic Design Automation, Metal, Ceramic, PM, DM, Hauck, Electronics, Aluminium, DSB, 3D, 316L, CAD, MIM, Multimedia, Desktop Metal, Zombie Movies: The Ultimate Guide, Stainless steel, Binder, Sport, NYSE, Powder metallurgy, 3D printing

Desktop Metal, Inc. (NYSE: DM), a global leader in additive manufacturing technologies for mass production, today announced that Wisconsin-based DSB Technologies (DSB), a leader in high-quality metal part production with sinter-based technologies such as powder metallurgy (PM) and metal injection molding (MIM) has now adopted the complete X-Series metal binder jetting product lineup, including Live Sinter software, from Desktop Metal.

Key Points: 
  • Desktop Metal, Inc. (NYSE: DM), a global leader in additive manufacturing technologies for mass production, today announced that Wisconsin-based DSB Technologies (DSB), a leader in high-quality metal part production with sinter-based technologies such as powder metallurgy (PM) and metal injection molding (MIM) has now adopted the complete X-Series metal binder jetting product lineup, including Live Sinter software, from Desktop Metal.
  • View the full release here: https://www.businesswire.com/news/home/20230912869954/en/
    Paul Hauck, Chief Operating Officer for DSB Technologies, based in Janesville, Wisconsin, explains why the company has adopted the entire line of Desktop Metal X-Series metal binder jetting 3D printers for production of metal parts.
  • It also plans to adopt Desktop Metal binder jetting for aluminum in the future.
  • “It's helping us solve application problems, get successful outcomes, and get there faster.”
    To learn more about metal binder jetting with DSB Technologies, visit www.dsbtech.com

ZCG-Backed Unimed Appoints Jesper Lok to Board of Directors

Retrieved on: 
Monday, June 26, 2023
Pharmaceutical, Medical Supplies, General Health, Health, Maritime, Logistics, Supply Chain Management, Transport, Other Health, Vaccine, Global Maritime Forum, Richard Cadell, DSB, Oxygen, Multimedia, Ship, Growth, Inchcape Shipping Services, Pharmaceutical industry, Management, Unimed, Maersk

Universal Marine Medical Supply International (“Unimed” or the “Company”), the leading global provider of pharmaceutical and medical solutions to the maritime industry and a ZCG portfolio company, today announced the appointment of Jesper Lok to its Board of Directors.

Key Points: 
  • Universal Marine Medical Supply International (“Unimed” or the “Company”), the leading global provider of pharmaceutical and medical solutions to the maritime industry and a ZCG portfolio company, today announced the appointment of Jesper Lok to its Board of Directors.
  • Mr. Lok brings more than 30 years of international Board and executive leadership experience to Unimed, including 25 years in various senior positions across Asia, Europe and Africa at Maersk, a global integrated logistics company.
  • “We are delighted to welcome Jesper to the Unimed Board of Directors.
  • Unimed specializes in providing a wide range of mission-critical medical and clinical supplies, including oxygen, surgery equipment, vaccines and pharmaceutical products.

OSFI reinforces resilience of Canada's financial system: Sets Domestic Stability Buffer at 3.5%

Retrieved on: 
Tuesday, June 20, 2023
Domestic, DSB, Financial institution, Superintendent, OSFI, Bank

OTTAWA, ON, June 20, 2023 /CNW/ - Today, the Office of the Superintendent of Financial Institutions (OSFI) raised the Domestic Stability Buffer (DSB) by 50 basis points to 3.5% of total risk-weighted assets, effective November 1, 2023.

Key Points: 
  • OTTAWA, ON, June 20, 2023 /CNW/ - Today, the Office of the Superintendent of Financial Institutions (OSFI) raised the Domestic Stability Buffer (DSB) by 50 basis points to 3.5% of total risk-weighted assets, effective November 1, 2023.
  • Should existing vulnerabilities intensify, or new risks arise, OSFI will take action to support the resilience of regulated entities as well as help safeguard the stability of the Canadian financial system.
  • The DSB is an important tool that helps ensure the stability of Canada's financial system and requires Canada's largest domestic systemically important banks (D-SIBs) to build up a capital buffer as vulnerabilities grow.
  • OSFI reviews and sets the DSB level every June and December but can make changes at other times as circumstances warrant.

Institute of Oncology Ljubljana Leverages SOPHiA DDM™ Platform for Cancer Research

Retrieved on: 
Wednesday, May 24, 2023
Database, DNA, Oncology, HRR, Education, HRD, BRCA1, DSB, Deep learning, Cancer, Breast, Research, Prostate, Sophia, Doctor of Science, Sophia Genetics, Platform, Algorithm, Biol, GENETICS, WGS, BRCA2, Health, IOL, Whole genome sequencing, Medical imaging

BOSTON and LAUSANNE, Switzerland, May 24, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that the Institute of Oncology Ljubljana (IOL), a comprehensive public institution for detection, treatment and research of cancer, based in Ljubljana, Slovenia, is live on SOPHiA DDM™. To help advance its clinical oncology research, IOL is leveraging low-pass Whole Genome Sequencing (WGS) data computed by the proprietary GIInger deep-learning algorithm from SOPHiA GENETICS to increase research efficiency and obtain actionable clinical insights to make data-driven decisions that improve the quality of patient care.

Key Points: 
  • "As the leading institution in the country for the detection, treatment and research of cancer, we work to ensure balanced and proper development of oncology health services.
  • This is why research and education hold a special position at the Institute," said Dr. Srdjan Novaković, DSc (Biol.
  • "Our work at SOPHiA GENETICS is to democratize data-driven medicine," said Esteban Czwan, Managing Director, EMEA, SOPHiA GENETICS.
  • With the cloud-based SOPHiA DDM™ Platform, the Institute of Oncology Ljubljana will amass an in-house database that will help to further their cancer research and progress for all of Slovenia.

David S. Brown Enterprises Welcomes Quest Management Group to Red Brook Corporate Center

Retrieved on: 
Thursday, May 18, 2023
Zurich Insurance Group, Partnership, DSB, MD, Investment, Pleasure, Paychex, NOI, MD Anderson Cancer Center, Management, Quest

, May 18, 2023 /PRNewswire/ -- Quest Management Group leases office space at 400 Red Brook Boulevard within the luxury suburban campus of Red Brook Corporate Center in Owings Mills, MD

Key Points: 
  • , May 18, 2023 /PRNewswire/ -- Quest Management Group leases office space at 400 Red Brook Boulevard within the luxury suburban campus of Red Brook Corporate Center in Owings Mills, MD
    With over 23 years of industry experience, Quest Management Group (Quest) brings a unique and seasoned approach to multi-family management.
  • Beginning as a small family run business, Quest has evolved through the years to a professionally staffed, multi-family management company which aligns the interests of investors, employees, and residents.
  • We will continue to support their goals by delivering unwavering customer service and top-tier amenities," stated Brent Mangum, Vice President of Office Leasing at David S. Brown Enterprises.
  • Quest Management Group operates 21 residential properties throughout Maryland, Ohio and Pennsylvania.

HuidaGene Therapeutics' Novel DNA Gene-Editing System Cas12i Patent Granted by USPTO

Retrieved on: 
Tuesday, May 16, 2023
SAB, Patent, DNA, CRISPR, Classification, PAM, Type 2, Gene editing, DSB, Rationality, Biomedical Research, Protein & Cell, Chromosomal deletion syndrome, Research, DSM-IV codes, Cell, RNA, Chromosomal rearrangement, AAV, Patient, Archaea, Apoptosis, Synergy, Entrepreneurship, Bacteria, AI, Viral, Therapy, Neurology, Protein, Cas12a, DNA repair, Vaccine, Pharmaceutical industry, Medical device, Cas9

Cas12Max® has the highest DNA editing efficiency in mammalian cells compared with Streptococcus pyogenes Cas9 (SpCas9) and Lachnospiraceae bacterium Cas12a (LbCas12a).

Key Points: 
  • Cas12Max® has the highest DNA editing efficiency in mammalian cells compared with Streptococcus pyogenes Cas9 (SpCas9) and Lachnospiraceae bacterium Cas12a (LbCas12a).
  • This fundamental patent covers multiple novel Cas12i proteins, and their variants and DNA editing uses thereof.
  • "My team has identified 10 novel Cas12i proteins through AI and deep ML of DNA sequencing and assembly prediction from metagenomic database followed by the identification of xCas12i through the fluorescent reporting system.
  • HuidaGene will continue to improve the CRISPR-based gene-editing technology and bring safe gene-editing therapies a reality for millions of patients worldwide.

HuidaGene Therapeutics' Novel DNA Gene-Editing System Cas12i Patent Granted by USPTO

Retrieved on: 
Tuesday, May 16, 2023
SAB, Patent, DNA, CRISPR, Classification, PAM, Type 2, Gene editing, DSB, Rationality, Biomedical Research, Protein & Cell, Chromosomal deletion syndrome, Research, DSM-IV codes, Cell, RNA, Chromosomal rearrangement, AAV, Patient, Archaea, Apoptosis, Synergy, Entrepreneurship, Bacteria, AI, Viral, Therapy, Neurology, Protein, Cas12a, DNA repair, Vaccine, Pharmaceutical industry, Medical device, Cas9

Cas12Max® has the highest DNA editing efficiency in mammalian cells compared with Streptococcus pyogenes Cas9 (SpCas9) and Lachnospiraceae bacterium Cas12a (LbCas12a).

Key Points: 
  • Cas12Max® has the highest DNA editing efficiency in mammalian cells compared with Streptococcus pyogenes Cas9 (SpCas9) and Lachnospiraceae bacterium Cas12a (LbCas12a).
  • This fundamental patent covers multiple novel Cas12i proteins, and their variants and DNA editing uses thereof.
  • "My team has identified 10 novel Cas12i proteins through AI and deep ML of DNA sequencing and assembly prediction from metagenomic database followed by the identification of xCas12i through the fluorescent reporting system.
  • HuidaGene will continue to improve the CRISPR-based gene-editing technology and bring safe gene-editing therapies a reality for millions of patients worldwide.

COGNIZANT REPORTS FIRST QUARTER 2023 RESULTS

Retrieved on: 
Wednesday, May 3, 2023
Cloud, FCCI, Workforce, Telecom, Guy-wire, Cognizant, Amazon Web Services, Medicaid, Nextgen, Travel, Partnership, Agility, Share repurchase, Department for Environment, Food and Rural Affairs, Telecommunications, Health care, DSB, Food, Microsoft, Jetstar, Government, Boehringer Ingelheim, Investment, City, Growth, Nike, Environment, Horizon, AWS, Veeva Systems, Cryptocurrency, Video game

The Company repurchased 3.2 million shares for $200 million during the first quarter under its share repurchase program.

Key Points: 
  • The Company repurchased 3.2 million shares for $200 million during the first quarter under its share repurchase program.
  • As of March 31, 2023, there was $2.6 billion remaining under the share repurchase authorization.
  • In May 2023, the Company declared a quarterly cash dividend of $0.29 per share, a 7% increase year-over-year, for shareholders of record on May 19, 2023.
  • Cognizant will host a conference call on May 3, 2023, at 5:00 p.m. (Eastern) to discuss the Company's first quarter 2023 results.

DSB Technologies Announces Metal 3D Printing Prototyping Service

Retrieved on: 
Wednesday, May 3, 2023
Hardware, Chemicals, Plastics, Electronic Design Automation, Automotive Manufacturing, Aerospace, Manufacturing, Technology, Robotics, Other Technology, Other Manufacturing, Machinery, Software, Machine Tools, Metalworking & Metallurgy, Steel, Engineering, DSB, 3D, 3D printing, SAE 316L stainless steel, Partnership, Multimedia, Part, Stainless steel

DSB Technologies, a world leader in the manufacturing of powder metal components, announced the launch of its Metal Binder Jetting prototyping services for a diverse customer base.

Key Points: 
  • DSB Technologies, a world leader in the manufacturing of powder metal components, announced the launch of its Metal Binder Jetting prototyping services for a diverse customer base.
  • View the full release here: https://www.businesswire.com/news/home/20230503005109/en/
    Part designed and produced for Metal Binder Jetting by DSB Technologies.
  • DSB Technologies remains committed to industrializing the Metal Binder Jetting process for serial production as it adds this 3D printing prototyping capability to its robust technology portfolio as a resource for educating the market on the technology’s capabilities.
  • With DSB Technologies’ prototyping service, customers can leverage a collaborative partnership to develop, design, and iterate applications for Metal Binder Jetting more efficiently.

Pusan National University Develops Novel Biosensor to Detect DNA Damage in Real Time

Retrieved on: 
Tuesday, March 14, 2023
Plasmid, Associate, FRET, H2AX, Environment, Pusan National University, Energy, Wireless power transfer, Cell, Fluorophore, DNA, DSB, Orientation, DNA repair, Drug discovery, Protein, Vaccine, Microscope

BUSAN, South Korea, March 14, 2023 /PRNewswire/ -- Scientists from Korea have developed a new biosensor that uses fluorescence resonance energy transfer (FRET) to detect DNA double-strand breaks in living specimens in real time. This biosensor has the potential to revolutionize cancer treatment by helping doctors understand how cells respond to treatment and facilitating the discovery of new DNA repair drugs. It can also aid the development of new treatments for DNA damage-related diseases by revealing how our bodies repair damaged DNA.

Key Points: 
  • It can also aid the development of new treatments for DNA damage-related diseases by revealing how our bodies repair damaged DNA.
  • Double-strand breaks (DSBs) are a type of DNA damage where both strands of DNA break at the same location.
  • Currently, DSBs are detected by immunostaining techniques, which identify markers that accompany DNA damage, such as the protein γH2AX.
  • However, these methods are tedious, and cannot be used to detect DSBs in real time in living specimens.